샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793611

세계의 경도인지장애 시장

Mild Cognitive Impairment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 369 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

경도인지장애 세계 시장은 2030년까지 26억 달러에 달할 전망

2024년에 20억 달러로 추정되는 경도인지장애 세계 시장은 분석 기간인 2024-2030년에 CAGR 4.3%로 성장하여 2030년에는 26억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 건망성 경도 치매 질환은 CAGR 3.4%를 기록하며 분석 기간 종료시에는 15억 달러에 달할 것으로 예측됩니다. 경도 치매 질환 부문의 성장률은 분석 기간 동안 CAGR 5.6%로 추정됩니다.

미국 시장은 5억 4,360만 달러로 추정, 중국은 CAGR 7.6%로 성장 예측

미국의 경도인지장애 시장은 2024년에 5억 4,360만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년 분석 기간 동안 CAGR 7.6%로 성장하여 2030년에는 5억 2,110만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.8%와 3.3%로 예측됩니다. 유럽에서는 독일이 CAGR 2.5%로 성장할 것으로 예측됩니다.

세계의 경도인지장애 시장 - 주요 동향과 촉진요인 정리

신경의학에서 경도인지장애는 어떻게 신경의학에서 중요한 초점이 되고 있는가?

경도인지장애(MCI)는 정상적인 노화와 치매 및 알츠하이머병과 관련된 더 심각한 쇠퇴 사이에 존재하는 중요한 신경학적 상태로 점점 더 많이 인식되고 있습니다. MCI는 기억력, 사고력 또는 추론의 현저한 변화를 특징으로 하며, 개인의 나이에 비해 예상보다 크지만 일상 생활에 큰 지장을 초래할 정도로 심각하지는 않습니다. 세계 인구의 급속한 고령화에 따라 MCI는 더 쇠약해지는 신경퇴행성 질환으로 발전할 가능성이 있어 공중보건의 우선순위로 주목받고 있습니다. 조기 인지 기능 저하에 대한 인식이 높아지면서 의료 서비스 제공자들은 선별 검사와 조기 진단에 더 많은 관심을 기울이고 있습니다. 또한 환자와 가족들도 건망증, 집중력 저하, 언어장애 등의 초기 증상에 민감하게 반응하여 더 많은 임상 진료와 평가를 받고 있습니다. MCI가 명확한 진단 범주로 등장하면서 신경과 의사들은 더 심각한 질환의 발병을 지연시키거나 예방하기 위한 중재 전략을 모색하게 되었습니다. 또한, 신체활동, 인지활동, 수면위생, 식습관 등 생활습관이 MCI 진행에 영향을 미칠 수 있다는 연구 결과가 있어 환자 치료에 다학제적 접근이 필요한 것으로 나타났습니다. 인지 재활 프로그램이나 디지털 인지 훈련 도구는 조기 기능 저하를 타겟으로 하여 기능을 유지하기 위해 개발되고 있습니다. MCI가 반드시 치매로 이어지는 것은 아니지만, MCI가 발견되면 개입, 모니터링, 지원을 위한 중요한 기회를 제공합니다. 초기 인지기능 변화에 대한 임상적, 사회적 관심이 높아지면서 MCI는 보다 광범위한 인지 및 신경 건강 분야의 중요한 연구 분야로 변모하고 있습니다.

조기 발견과 진단이 MCI 연구와 치료의 혁신을 촉진하는 이유는 무엇인가?

조기 발견과 진단은 진단 기술, 위험 평가, 임상 경로의 혁신을 촉진하고 경미한 인지 장애를 관리하기 위한 노력의 중심이 되고 있습니다. MCI를 조기에 발견하면 인지기능 저하를 늦추거나 안정화시킬 수 있는 중재를 시행할 수 있는 중요한 시간을 확보할 수 있습니다. 헬스케어 시스템에서는 몬트리올 인지기능평가(MoCA), 미니정신상태검사(MMSE) 등 표준화된 인지기능 평가와 실시간 인지기능 모니터링 및 원격 검사 기능을 제공하는 새로운 디지털 도구의 도입이 진행되고 있습니다. 바이오마커 연구도 빠르게 진행되고 있으며, 신경영상, 뇌척수액 분석, 혈액 기반 검사 등이 MCI와 정상 노화 및 초기 알츠하이머병 병리와의 감별을 위해 연구되고 있습니다. 인공지능과 머신러닝 모델은 환자 데이터를 분석하고 치매로의 진행 가능성을 예측하기 위해 개발되고 있으며, 임상의에게 강력한 새로운 의사결정 수단을 제공하고 있습니다. 유전자 검사와 맞춤형 의료 접근법은 특히 인지장애의 가족력이나 APOE4 유전자 변이체 등 알려진 위험 요인을 가진 환자에서 위험 프로파일링을 더욱 정교하게 만들고 있습니다. 이러한 발전은 조기 발견을 도울 뿐만 아니라 보다 정확하고 표적화된 치료 개입의 개발을 형성하고 있습니다. 제약회사들이 MCI의 인지기능 저하를 지연시키거나 막는 데 초점을 맞춘 임상시험에 투자하는 가운데, 진단 기술 혁신은 적격 환자를 식별하고 치료 결과를 추적하는 데 필수적인 요소로 자리 잡고 있습니다. 또한, 조기 진단을 통해 적극적인 생활 설계, 동반 질환의 더 나은 관리, 지원 서비스 이용이 가능해져 환자와 보호자에게 힘을 실어줄 수 있습니다. 전 세계 의료 기관이 조기 인지 건강을 노화 관리의 초석으로 강조하는 가운데, 조기 발견을 촉진하는 것은 MCI의 연구 과제와 의료 서비스 제공 모델 모두를 재구성하고 있습니다.

생활습관 중재와 비약리학적 전략이 MCI 관리에 어떤 영향을 미치고 있는가?

비약리학적 전략과 생활습관 개입은 인지기능 저하를 지연시키는 효과가 있다는 증거가 증가함에 따라 MCI 관리에서 점점 더 중요한 역할을 하고 있습니다. 현재 MCI에 대해 FDA가 승인한 약물은 없지만, 연구에 따르면 신체 활동, 인지 자극, 사회 참여, 영양을 목표로 하는 구조화된 개입이 인지 능력과 전반적인 삶의 질에 상당한 이점을 가져다주는 것으로 나타났습니다. 걷기, 자전거 타기, 근력 운동과 같은 유산소 운동은 뇌 혈류를 촉진하고 신경 가소성을 촉진하여 실행 기능 및 기억력 향상과 관련이 있습니다. 대면 또는 디지털 방식으로 진행되는 인지 훈련 프로그램은 주의력, 처리 속도, 언어 유창성 등 특정 인지 영역을 강화하는 데 도움이 됩니다. 또한, 과일, 채소, 통곡물, 건강한 지방, 저지방, 저지방 단백질을 강조하는 지중해식, MIND 식단 등의 식습관이 신경 보호 효과의 가능성을 연구하고 있습니다. 마음챙김, 명상, 충분한 수면 위생도 스트레스 감소와 인지 기능 유지에 도움이 될 수 있습니다. 지역사회에 기반을 둔 프로그램이나 집단 개입은 사회적 유대감을 형성하고 인지기능 저하를 예방하는 것으로 인식되고 있습니다. 의료 서비스 제공자는 이러한 라이프스타일 전략을 통합한 개인별 케어 플랜을 개발하고 있으며, 간병인과 가족도 함께 참여하여 일관성과 참여도를 높이고 있습니다. 공중 보건 노력과 인식 개선 캠페인은 특히 노인 집단에서 광범위한 인지 건강 전략의 일환으로 이러한 개입을 장려하고 있습니다. 이러한 전인적이고 환자 중심적인 관리로의 전환은 MCI가 행동적, 환경적, 유전적 요인에 의해 영향을 받는 다인성 질환이라는 깊은 이해를 반영하며, 인지 노화에서 생활습관이 중요한 역할을 한다는 점을 강조합니다.

전 세계적으로 경도인지장애에 대한 관심이 높아진 주요 요인은 무엇일까?

경도인지장애에 대한 전 세계적인 관심은 인구통계학적, 임상적, 사회적, 기술적 요인이 복합적으로 작용하고 있습니다. 그 중 가장 대표적인 것이 세계 인구의 고령화이며, MCI를 포함한 노화에 따른 인지장애의 급증으로 이어지고 있습니다. 수명이 길어짐에 따라 인지기능 저하의 유병률도 증가하고 있으며, MCI는 치매와 알츠하이머병으로의 진행을 예방하기 위한 조기 개입의 중요한 표적이 되고 있습니다. 대중의 인식 개선 캠페인과 교육 이니셔티브는 인지 기능의 변화에 대한 인식을 개선하고, 조기 진단과 의료 서비스 참여를 독려하고 있습니다. 동시에 신경과학과 진단학의 발전으로 인지 기능 장애를 보다 정확하게 식별하고 계층화하여 적시에 적절한 개입을 할 수 있는 기회가 생기고 있습니다. 의료제도와 정부가 조기발견과 조기치료에 투자함으로써 장기적인 치료비용을 절감하고자 하기 때문입니다. 제약회사와 생명공학 기업들도 MCI를 임상 혁신의 중요한 진입점으로 인식하고 조기 인지기능저하 치료법 개발을 위한 연구 노력을 강화하고 있습니다. 또한, 디지털 헬스 기술의 보급은 지속적인 인지 평가와 원격 환자 모니터링을 지원하여 인지 치료를 보다 친숙하고 확장 가능하게 만들고 있습니다. 정책 입안자들과 보험사들은 조기 개입 프로그램의 장기적인 가치를 인식하고 있으며, 이는 인지 의료 서비스에 대한 보상 정책 및 재정 지원으로 이어지고 있습니다. 이러한 복합적인 요인들이 MCI에 초점을 맞춘 세계 이니셔티브의 강력한 모멘텀을 창출하고 있으며, MCI는 고령화와 뇌 건강의 광범위한 맥락에서 도전이자 기회로 인식되고 있습니다. MCI에 대한 이해가 높아짐에 따라 개인적 차원이든 시스템 차원이든 MCI에 대처하기 위한 노력의 시급성과 협력성이 높아지고 있습니다.

부문

질환(건망성 경도 치매, 경도 치매), 적응증(루이소체 치매, 파킨슨병, 알츠하이머병, 혈관성 치매, 기타 적응증), 치료(약물, 요법)

조사 대상 기업 사례

  • AbbVie Inc.
  • AC Immune SA
  • Alzheon, Inc.
  • Alector, Inc.
  • Anavex Life Sciences Corp.
  • Biogen Inc.
  • Cassava Sciences, Inc.
  • Cognivue, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Genentech(Roche Group)
  • Huron Digital Pathology
  • Johnson & Johnson
  • Karuna Therapeutics
  • MedRhythms, Inc.
  • Neurotrack Technologies, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Roche Holding AG
  • Sage Therapeutics, Inc.
  • Takeda Pharmaceutical Company

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.27

Global Mild Cognitive Impairment Market to Reach US$2.6 Billion by 2030

The global market for Mild Cognitive Impairment estimated at US$2.0 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Amnestic Disease, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Non-Amnestic Disease segment is estimated at 5.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$543.6 Million While China is Forecast to Grow at 7.6% CAGR

The Mild Cognitive Impairment market in the U.S. is estimated at US$543.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$521.1 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Mild Cognitive Impairment Market - Key Trends & Drivers Summarized

How Is Mild Cognitive Impairment Emerging as a Critical Focus in Neurological Health?

Mild Cognitive Impairment (MCI) is increasingly recognized as a significant neurological condition that exists between normal aging and the more severe decline associated with dementia and Alzheimer’s disease. It is characterized by noticeable changes in memory, thinking, or reasoning that are greater than expected for an individual’s age but not severe enough to interfere significantly with daily activities. With the global population aging rapidly, MCI has gained prominence as a public health priority due to its potential to progress into more debilitating neurodegenerative diseases. The rising awareness of early cognitive decline has prompted healthcare providers to place greater emphasis on screening and early diagnosis. Patients and families are also becoming more attuned to the early signs, such as forgetfulness, difficulty concentrating, and trouble finding words, leading to more clinical consultations and evaluations. MCI’s emergence as a distinct diagnostic category has encouraged neurologists to explore intervention strategies that could slow or prevent the onset of more serious conditions. Furthermore, research indicates that lifestyle factors such as physical activity, cognitive engagement, sleep hygiene, and diet may influence the progression of MCI, prompting broader interdisciplinary involvement in patient care. Cognitive rehabilitation programs and digital cognitive training tools are being developed to target early-stage decline and preserve function. While MCI does not always lead to dementia, its identification provides a critical window of opportunity for intervention, monitoring, and support. This growing clinical and societal focus on early cognitive changes is transforming MCI into a key area of study within the broader field of cognitive and neurological health.

Why Is Early Detection and Diagnosis Driving Innovation in MCI Research and Treatment?

Early detection and diagnosis are becoming central to efforts in managing Mild Cognitive Impairment, prompting innovation in diagnostic technologies, risk assessments, and clinical pathways. Recognizing MCI at an early stage can provide critical time for implementing interventions that may slow or stabilize cognitive decline. Healthcare systems are increasingly adopting standardized cognitive assessments such as the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), as well as new digital tools that offer real-time cognitive monitoring and remote testing capabilities. Biomarker research is also advancing rapidly, with neuroimaging, cerebrospinal fluid analysis, and blood-based tests being explored to differentiate MCI from normal aging and early Alzheimer’s pathology. Artificial intelligence and machine learning models are being developed to analyze patient data and predict the likelihood of progression to dementia, offering clinicians powerful new decision-making tools. Genetic testing and personalized medicine approaches are further refining risk profiling, particularly in patients with a family history of cognitive disorders or known risk factors such as APOE4 gene variants. These advancements are not only aiding early detection but are also shaping the development of more precise and targeted therapeutic interventions. As pharmaceutical companies invest in clinical trials focused on delaying or halting cognitive decline in MCI, diagnostic innovation is becoming indispensable in identifying eligible patients and tracking therapeutic outcomes. Moreover, early diagnosis empowers patients and caregivers by enabling proactive life planning, better management of comorbidities, and access to supportive services. With global health organizations emphasizing early cognitive health as a cornerstone of aging care, the drive for early detection is reshaping both the research agenda and the healthcare delivery model for MCI.

How Are Lifestyle Interventions and Non-Pharmacological Strategies Impacting MCI Management?

Non-pharmacological strategies and lifestyle interventions are playing an increasingly important role in the management of Mild Cognitive Impairment, driven by a growing body of evidence that supports their efficacy in slowing cognitive decline. While there is currently no FDA-approved medication specifically for MCI, research has shown that structured interventions targeting physical activity, cognitive stimulation, social engagement, and nutrition can significantly benefit cognitive performance and overall quality of life. Aerobic exercises such as walking, cycling, and strength training have been linked to improved executive function and memory by enhancing cerebral blood flow and promoting neuroplasticity. Cognitive training programs, both in-person and digital, are helping patients strengthen specific cognitive domains such as attention, processing speed, and verbal fluency. Additionally, dietary patterns such as the Mediterranean and MIND diets, which emphasize fruits, vegetables, whole grains, healthy fats, and lean proteins, are being studied for their potential neuroprotective effects. Mindfulness practices, meditation, and adequate sleep hygiene are also showing promise in reducing stress and preserving cognitive function. Community-based programs and group interventions are fostering social connectivity, which is increasingly recognized as protective against cognitive deterioration. Healthcare providers are developing personalized care plans that incorporate these lifestyle strategies, often involving caregivers and family members to reinforce consistency and engagement. Public health initiatives and awareness campaigns are promoting these interventions as part of broader cognitive health strategies, particularly among aging populations. This shift toward holistic, patient-centered management reflects a deeper understanding of MCI as a multifactorial condition influenced by behavioral, environmental, and genetic factors, and highlights the critical role of lifestyle in cognitive aging.

What Are the Main Drivers Behind the Rising Global Focus on Mild Cognitive Impairment?

The growth in global focus on Mild Cognitive Impairment is being driven by a confluence of demographic, clinical, societal, and technological factors. Foremost among these is the aging global population, which is leading to a sharp rise in age-related cognitive disorders, including MCI. As longevity increases, so does the prevalence of cognitive decline, making MCI a critical target for early intervention to prevent the escalation to dementia and Alzheimer’s disease. Public awareness campaigns and education initiatives are improving recognition of cognitive changes, encouraging earlier healthcare engagement and diagnosis. At the same time, advances in neuroscience and diagnostics are enabling more accurate identification and stratification of cognitive impairment, creating opportunities for timely and tailored interventions. The economic impact of dementia-related illnesses is another significant driver, as health systems and governments seek to reduce the long-term costs of care by investing in early-stage detection and treatment. Pharmaceutical and biotechnology companies are also intensifying research efforts aimed at developing therapies for early cognitive decline, viewing MCI as a key entry point for clinical innovation. Additionally, the proliferation of digital health technologies is supporting continuous cognitive assessment and remote patient monitoring, making cognitive care more accessible and scalable. Policymakers and insurers are recognizing the long-term value of early intervention programs, leading to supportive reimbursement policies and funding for cognitive health services. These combined factors are creating a strong momentum behind global initiatives focused on MCI, positioning it as both a challenge and an opportunity in the broader context of aging and brain health. As the understanding of MCI evolves, so does the urgency and coordination of efforts to address it at both individual and systemic levels.

SCOPE OF STUDY:

The report analyzes the Mild Cognitive Impairment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease (Amnestic Disease, Non-Amnestic Disease); Indication (Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication, Other Indications); Treatment (Medication Treatment, Therapy Treatment)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc.
  • AC Immune SA
  • Alzheon, Inc.
  • Alector, Inc.
  • Anavex Life Sciences Corp.
  • Biogen Inc.
  • Cassava Sciences, Inc.
  • Cognivue, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Genentech (Roche Group)
  • Huron Digital Pathology
  • Johnson & Johnson
  • Karuna Therapeutics
  • MedRhythms, Inc.
  • Neurotrack Technologies, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Roche Holding AG
  • Sage Therapeutics, Inc.
  • Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Mild Cognitive Impairment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Aging Population Worldwide Throws the Spotlight on Mild Cognitive Impairment as a Public Health Priority
    • Growing Awareness and Early Diagnosis Campaigns Propel Demand for MCI Screening and Monitoring Tools
    • Advancements in Neuroimaging and Biomarker Development Strengthen the Business Case for Precision MCI Diagnostics
    • Shift Toward Preventive Neurology Expands the Addressable Market for Early-Stage Cognitive Therapeutics
    • Integration of Digital Health Platforms and Cognitive Assessment Apps Drives Adoption of At-Home Monitoring for MCI
    • Link Between Cardiovascular Health and Cognitive Decline Spurs Multi-Disciplinary Approaches in MCI Management
    • Rising Incidence of Lifestyle-Linked Cognitive Disorders Sustains Growth in Non-Pharmacological Interventions
    • Push for FDA Approval of Disease-Modifying Therapies Throws the Spotlight on the MCI Pipeline in Alzheimer's Spectrum
    • Adoption of AI and Machine Learning in Cognitive Analytics Drives Innovation in Early Detection Algorithms
    • Stigma Reduction and Mental Health Awareness Generate Opportunities for Community-Based MCI Support Programs
    • Challenges in Differentiating MCI from Normal Aging Highlight the Need for Standardized Diagnostic Criteria
    • Use of Wearables and Remote Patient Monitoring Tools Expands Real-Time Tracking of Cognitive Function in MCI Patients
    • Growing Employer and Insurer Interest in Cognitive Health Drives Corporate Wellness Integration of MCI Screening
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mild Cognitive Impairment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mild Cognitive Impairment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mild Cognitive Impairment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Amnestic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Amnestic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Amnestic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Amnestic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Amnestic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Non-Amnestic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Lewy Body Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Lewy Body Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Lewy Body Dementia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Parkinson's Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Parkinson's Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Parkinson's Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Alzheimer's Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Alzheimer's Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Alzheimer's Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Vascular Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Vascular Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Vascular Dementia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Medication Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • JAPAN
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • CHINA
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • EUROPE
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Mild Cognitive Impairment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Mild Cognitive Impairment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • FRANCE
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • GERMANY
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Mild Cognitive Impairment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • INDIA
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Mild Cognitive Impairment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Mild Cognitive Impairment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Mild Cognitive Impairment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Mild Cognitive Impairment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • AFRICA
    • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제